Drug Approval
Name: Elucirem
Active Ingredient: gadopiclenol
Indications: To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
Approval Date: 9/21/2022
Company: Guerbet LLC
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf